Nabel, Katherine G.Clark, Sarah A.Shankar, SundareshPan, JunhuaClark, LarsYang, PanCoscia, AdrianMcKay, Lindsay G.A.Varnum, HaleyBrusic, VesnaTolan, Nicole V.Zhou, GuohaiDesjardins, MichaëlTurbett, Sarah E.Kanjilal, SanjatSherman, AmyDighe, AnandLaRocque, Regina C.Ryan, EdwardTylek, CaseyCohen-Solal, Joel F.Darcy, Andhao T.Tavella, DavideClabbers, AncaFan, YaoGriffiths, AnthonyCorreia, Ivan R.Seagal, JaneBaden, LindseyCharles, RichelleAbraham, Jonathan2023-05-222021-12-02Nabel, Katherine G., Sarah A. Clark, Sundaresh Shankar, Junhua Pan, Lars E. Clark, Pan Yang, Adrian Coscia, et al. 2022. “Structural Basis for Continued Antibody Evasion by the SARS-CoV-2 Receptor Binding Domain.” Science (American Association for the Advancement of Science) 375 (6578): 282–eabl6251.https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37375297Many studies have examined the impact of SARS-CoV-2 variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor-binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.en-USJournal Article2023-05-2210.1126/science.abl6251